Enhancing Adaptations to Exercise

PHASE3CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Inflammation
Interventions
DRUG

n3-PUFA

The DHA/EPA softgels will each contain \~465mg of EPA and \~375mg of DHA for a total daily dosage of 3.4g/day. Additionally, each capsule will contain SCI's proprietary Advance Lipid TechnologiesTM (ALTTM) containing the surfactants polysorbate 80, NF (\~381 mg) and poloxamer 237, NF (\~8.8 mg).

DRUG

Placebo

Looks exactly like the study drug but contains soybean oil with no active ingredient.

PROCEDURE

Biopsy

Two muscle biopsies from the upper part of one leg. A small (\~1cm) incision will be made through the skin, and a needle will then be used to remove the muscle.

DIAGNOSTIC_TEST

Body Composition Scan

Measure of body fat percentage, skeletal muscle mass, body water, and visceral fat.

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

collaborator

National Center for Research Resources (NCRR)

NIH

lead

Mayo Clinic

OTHER